Drugs / EDV-GC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07049055 | Jan 2026 → Sep 2028 expected | pancreatic ductal adenocarcinoma | Engeneic Pty Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-01 | Engeneic Pty Limited | Results Abstract accepted to the Annual Meeting of the American Society of Clinical Oncology 2020 engeneic.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-01 | Engeneic Pty Limited | Abstract accepted to the Annual Meeting of the American Society of Clinical Oncology 2020 engeneic.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDV-GC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07049055 ↗ |
| Modality | Other / unclassified | “EDVs are bacterially derived nanocells 400 nm in diameter” NCT07049055 ↗ |
| Route | Intravenous | “Doses of E-EDV-D682/GC in 3mL of 0.9% sodium chloride are administered intravenously over 10 seconds.” NCT07049055 ↗ |